- The first subjects have been treated in an open-label Phase 2 basket study (Study 206) evaluating Allena Pharmaceuticals' (NASDAQ:ALNA) lead candidate ALLN-177 in adults and adolescents with primary hyperoxaluria or enteric hyperoxaluria with advanced kidney disease and elevated plasma oxalate.
- The trial will enroll 15-20 patients who will receive ALLN-177 for 12 consecutive weeks. The key endpoints are the change from baseline in 24-hour urinary oxalate excretion and plasma oxalate levels.
- According to ClinicalTrials.gov, the estimated primary completion date is June 2019.
- ALLN-177 is an orally available enzyme, oxalate decarboxylase, designed to degrade oxalate in the GI tract.
Allena Pharma's mid-stage basket study of ALLN-177 in hyperoxaluria underway
Recommended For You
More Trending News
About ALNAQ Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ALNAQ | - | - |
Allena Pharmaceuticals, Inc. |